Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations Reply

被引：0
作者：
Kristeleit, Rebecca [1 ]
Oza, Amit M. [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London SE1 9RT, England
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E315 / E315
页数：1
相关论文
共 4 条
  • [1] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    Colombo, N.
    Sessa, C.
    du Bois, A.
    Ledermann, J.
    McCluggage, W. G.
    McNeish, I.
    Morice, P.
    Pignata, S.
    Ray-Coquard, I.
    Vergote, I.
    Baert, T.
    Belaroussi, I.
    Dashora, A.
    Olbrecht, S.
    Planchamp, F.
    Querleu, D.
    Baert, T.
    Banerjee, S.
    Belaroussi, I.
    Blecharz, P.
    Bruchim, I.
    Cibula, D.
    Colombo, N.
    Concin, N.
    Davidson, B.
    Dashora, A.
    Devouassoux-Shisheboran, M.
    du Bois, A.
    Ferrero, A.
    Glasspool, R.
    Gonzalez-Martin, A.
    Heinzelmann-Schwarz, V.
    Joly, F.
    Kim, J. W.
    Kridelka, F.
    Ledermann, J.
    Lorusso, D.
    Mahner, S.
    McCluggage, W. G.
    McNeish, I.
    Mikami, M.
    Mirza, M. R.
    Morice, P.
    Nicum, S.
    Olbrecht, S.
    O'Donnell, D. M.
    Pautier, P.
    Planchamp, F.
    Pignata, S.
    Querleu, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 672 - 705
  • [2] Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
    Kristeleit, Rebecca
    Lisyanskaya, Alla
    Fedenko, Alexander
    Dvorkin, Mikhail
    de Melo, Andreia Cristina
    Shparyk, Yaroslav
    Rakhmatullina, Irina
    Bondarenko, Igor
    Colombo, Nicoletta
    Svintsitskiy, Valentyn
    Biela, Luciano
    Nechaeva, Marina
    Lorusso, Domenica
    Scambia, Giovanni
    Cibula, David
    Poka, Robert
    Oaknin, Ana
    Safra, Tamar
    Mackowiak-Matejczyk, Beata
    Ma, Ling
    Thomas, Daleen
    Lin, Kevin K.
    McLachlan, Karen
    Goble, Sandra
    Oza, Amit M.
    [J]. LANCET ONCOLOGY, 2022, 23 (04) : 465 - 478
  • [3] Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
    Poveda, A.
    Vergote, I.
    Tjulandin, S.
    Kong, B.
    Roy, M.
    Chan, S.
    Filipczyk-Cisarz, E.
    Hagberg, H.
    Kaye, S. B.
    Colombo, N.
    Lebedinsky, C.
    Parekh, T.
    Gomez, J.
    Park, Y. C.
    Alfaro, V.
    Monk, B. J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (01) : 39 - 48
  • [4] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David
    Ray-Coquard, Isabelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
1